About Dylan Sammut
Dylan joined Irving Levin in October 2018 as a Research and Editorial Associate and is responsible for reporting on mergers and acquisitions in the healthcare sector. He graduated from Alfred University in May 2014 with a degree in English and Political Science. He currently lives in Bridgeport, CT with his fiancé and his overweight cat, Kimba, and in his free time he plays video games, reads, writes, and hikes on the weekends all year around.
by Dylan Sammut | Oct 14, 2019 12:41 pm | Other Services
Cinven, the London-based private equity firm, struck a deal last week to acquire National Seating & Mobility (NMS) from Court Square Capital Partners. The sale, which was valued at $850 million by sources cited in PEHub Buyouts, resulted from a Harris Williams-run... Read More »
by Dylan Sammut | Oct 14, 2019 12:33 pm | Biotechnology
The global biopharmaceutical company UCB (Brussels: UCB) announced it is acquiring Ra Pharmaceuticals (NASDAQ: RARX) for $2.1 billion. Ra Pharma is a clinical-stage biopharmaceutical company that develops novel therapeutics for the treatment of serious diseases caused... Read More »
by Dylan Sammut | Oct 11, 2019 4:04 pm | Healthcare Market Updates
The Health Care M&A Weekly chart is a selection of transactions announced during the prior week(s). The deals presented here are from our Deal Search Online database, which is updated every business day. Visit www.dealsearchonline.com to see how Deal Search Online... Read More »
by Dylan Sammut | Oct 7, 2019 2:47 pm | Healthcare Market Updates
The Health Care M&A Weekly chart is a selection of transactions announced during the prior week(s). The deals presented here are from our Deal Search Online database, which is updated every business day. Visit www.dealsearchonline.com to see how Deal Search Online... Read More »
by Dylan Sammut | Oct 7, 2019 2:08 pm | Pharmaceuticals
Swedish Orphan Biovitrum AB (STO: SOBI), an international specialty healthcare company dedicated to rare diseases, announced its acquisition of Dova Pharmaceuticals, Inc. for $867.7 million (65.3x revenue), or 27$ per share. Dova acquires, develops and commercializes... Read More »